Therese Bittermann, MD, MSCE
Assistant Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania
Research Non-Traditional Personnel (NTP), Division of Gastroenterology, Hepatology and Nutrition,
Department of Pediatrics,
Children's Hospital of Philadelphia,
Philadelphia, PA
Research Without Compensation (WOC) appointment, Division of Gastroenterology,
Department of Medicine,
Corporal Michael J. Crescenz VA Medical Center,
Philadelphia, PA
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Medical Director, Living Donor Liver Transplant Program,
Penn Transplant Institute,
University of Pennsylvania
Associate Member, NIH P30 Center for Molecular Studies in Digestive and Liver Disease
Research Associate, NIH P30 Population Aging Research Center
Department: Medicine
Contact information
Hospital of the University of Pennsylvania
Penn Transplant Institute
2 Dulles
3400 Spruce Street
Philadelphia, PA 19104
Penn Transplant Institute
2 Dulles
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
Fax: 215-349-5915
Education:
BA (Biological Sciences; International Studies)
Northwestern University, 2005.
MS (Physiology and Biophysics)
Georgetown University, 2006.
MD (Medicine)
Drexel University College of Medicine, 2010.
MS (Clinical Epidemiology)
University of Pennsylvania, 2017.
Permanent linkBA (Biological Sciences; International Studies)
Northwestern University, 2005.
MS (Physiology and Biophysics)
Georgetown University, 2006.
MD (Medicine)
Drexel University College of Medicine, 2010.
MS (Clinical Epidemiology)
University of Pennsylvania, 2017.
Description of Clinical Expertise
I care for patients with viral hepatitis, auto-immune diseases of the liver, fatty liver disease, liver tumors, and cirrhosis. I also have expertise in pre- and post-transplantation management.Description of Research Expertise
I study the relationship between immunosuppression strategy and outcomes after liver transplantation. I have previous expertise in research related to organ allocation, living donor liver transplantation, the effects of transplant policy-making, disparities in liver care and center variability in patient care. These efforts have spanned adult and pediatric transplant populations. I also have research interests in autoimmune hepatitis and alcohol-associated liver disease. I have an advanced degree in clinical epidemiology, and have expertise with observational study designs, large databases and statistics.Selected Publications
Bittermann T, Kathawate RG, Schaubel DE, Lewis JD, Goldberg DS: Hospital readmission for acute kidney injury is independently associated with de novo end-stage renal disease after liver transplantation. Liver Transplantation 31(2): 140-150, Feb 2025.Bittermann T, Yagan L, Kathawate RG, Weinberg EM, Peyster EG, Lewis JD, Levy C, Goldberg DS: Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis Hepatology 81(2): 423-35, Feb 2025.
Bennett AD, Morales KH, Huang YV, Tam V, Shah A, Loomes KM, Serper M, Bittermann T.: Lower child opportunity index is associated with increased healthcare utilization following pediatric liver transplantation Liver Transplantation Epub ahead of print, Feb 2025.
Banker A, Cywes C, Muñoz N, Taj R, Bittermann T, Abt P, Abu Gazala S: The Impact of Donor Body Mass Index on Safety and Outcomes in Living Donor Liver Transplantation: An Analysis of the National United States Database Transplantation Direct 82(2): 268-276, Feb 2025.
Durkin C, Schaubel DE, Kaplan DE, Mahmud N, Bittermann T: Survival Benefit From Corticosteroids in Severe Alcohol-associated Hepatitis Attributed to Clinical and Treatment Differences in a Large Multicenter Cohort Clinical and Translational Gastroenterology 16(1): e00791, Jan 2025.
Barr LG, Abt P, Rand EB, Bittermann T: Waitlist outcomes of pediatric liver transplant recipients relisted as adults. Liver Transplantation 31(1): 125-8, Jan 2025.
Bittermann T, Schaubel DE: Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue? Hepatology Epub ahead of print, Dec 2024.
Wang RX, Lee JJ, Mirda D, Hao J, Goebel AM, Deutsch-Link S, Serper M, Bittermann T: Association of psychosocial risk factors and liver transplant evaluation outcomes in metabolic dysfunction-associated steatotic liver disease Liver Transplantation 30(12): 1226-37, Dec 2024.
Cywes C, Banker A, Munoz N, Levine M, Abu-Gazala S, Bittermann T, Abt P: The Potential Utilization of Machine Perfusion to Increase Transplantation of Macrosteatotic Livers. Transplantation 108(11): e370-e375, Nov 2024.
Bittermann T, Byhoff E: CON: Satellite clinics are a marketing tool and do not improve access and equity in liver transplantation. Liver Transplantation 30(10): 1082-5, Oct 2024.